Top

Published in:

Open Access 01-12-2014 | Research

The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer

Authors: Yoko Matsushita, Yoshihito Yokoyama, Hidemi Yoshida, Yuki Osawa, Makito Mizunuma, Tatsuhiko Shigeto, Masayuki Futagami, Tadaastu Imaizumi, Hideki Mizunuma

Published in: Journal of Ovarian Research | Issue 1/2014

Abstract

Background

The human RECQ DNA helicase family is involved in genomic stability. Gene mutations of RECQL2, RECQL3, and RECQL4 are associated with genetic disorders and induce early aging and carcinogenesis. Although previous studies have reported that the level of RECQL1 expression is correlated with the prognosis of some of malignancies, the function of RECQL1 is not yet clarified. The present study aimed to examine the relationship between prognosis and the level of RECQL1 expression in epithelial ovarian cancer (EOC), and to identify the role of RECQL1 in EOC cells.

Methods

The level of RECQL1 expression was determined immunohistochemically in 111 patients with EOC who received initial treatment at Hirosaki University hospital between 2006 and 2011. Effects of RECQL1 on cell growth or apoptosis were examined in vitro using wild-type and OVCAR-3 cells (RECQL1(+) cells) and similar cells transfected with RECQL1 siRNA transfected (RECQL1(−) cells).

Results

The level of RECQL1 expression was not related to histological type, clinical stage, or retroperitoneal lymph node metastasis, but the expression level was significantly higher (P = 0.002) in patients with recurrence than those without recurrence, and progression-free survival and complete response rate to chemotherapy were also improved in patients with RECQL1-low expression (n = 39) stage III/IV EOC (P = 0.02 and P <0.05 vs RECQL1-high expression patients (n = ), respectively). A cell proliferation and colony formation assays revealed significantly less growth of RECQL1(−) cells compared to RECQL1(+) cells. A flow cytometry using annexin V -FITC and propidium iodide (PI) staining revealed a significant increase in apoptotic RECQL1(−) cells. Cell cycle analysis showed a significantly greater distribution in subG1 phase indicating apoptotic cells in RECQL1(−) cells than in RECQL1(+) cells.

Conclusions

These results suggest that RECQL1 is a prognostic factor for EOC and that RECQL1 contributes to potential malignancy by inhibiting apoptosis.

Available only for authorised users

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013,63(1):11–30. 10.3322/caac.21166CrossRefPubMed

Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95: S161-S192. 10.1016/S0020-7292(06)60033-7CrossRefPubMed

Yokoyama Y, Futagami M, Watanabe J, Sato N, Terada Y, Miura F, Sugiyama T, Takano T, Yaegashi N, Kojimahara T, Kurachi H, Nishiyama H, Fujimori K, Tase T, Mizunuma H: Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer. Mol Clin Oncol 2014,2(2):212–218.PubMedCentralPubMed

Nakayama H, Nakayama K, Nakayama R, Irino N, Nakayama Y, Hanawalt PC: Isolation and genetic characterization of a thymineless death-resistant mutant of Escherichia coli K12: identification of a new mutation (recQ1) that blocks the RecF recombination pathway. Mol Gen Genet 1984,195(3):474–480. 10.1007/BF00341449CrossRefPubMed

Sinclair DA, Guarente L: Extrachromosomal rDNA circles–a cause of aging in yeast. Cell 1997,91(7):1033–1042. 10.1016/S0092-8674(00)80493-6CrossRefPubMed

Furuichi Y: Premature aging and predisposition to cancers caused by mutations in RecQ family helicases. Ann N Y Acad Sci 2001, 928: 121–131. 10.1111/j.1749-6632.2001.tb05642.xCrossRefPubMed

Kitao S, Shimamoto A, Goto M, Miller RW, Smithson WA, Lindor NM, Furuichi Y: Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 1999,22(1):82–84. 10.1038/8788CrossRefPubMed

Hickson ID, Davies SL, Li JL, Levitt NC, Mohaghegh P, North PS, Wu L: Role of the Bloom's syndrome helicase in maintenance of genome stability. Biochem Soc Trans 2001, 29: 201–204. 10.1042/BST0290201CrossRefPubMed

Watt PM, Hickson ID, Borts RH, Louis EJ: SGS1, a homologue of the Bloom’s and Werner’s syndrome genes, is required for maintenance of genome stability in Saccharomyces cerevisiae. Genetics 1996,144(3):935–945.PubMedCentralPubMed

10.

Seki M, Miyazawa H, Tada S, Yanagisawa J, Yamaoka T, Hoshino S, Ozawa K, Eki T, Nogami M, Okumura K, Taguchi H, Hanaoka F, Enomoto T: Molecular cloning of cDNA encoding human DNA helicase Q1 which has homology to Escherichia coli Rec Q helicase and localization of the gene at chromosome 12p12. Nucleic Acids Res 1994,22(22):4566–4573. 10.1093/nar/22.22.4566PubMedCentralCrossRefPubMed

11.

Thangavel S, Mendoza-Maldonado R, Tissino E, Sidorova JM, Yin J, Wang W, Monnat RJ Jr, Falaschi A, Vindigni A: Human RECQ1 and RECQ4 helicases play distinct roles in DNA replication initiation. Mol Cell Biol 2010,30(6):1382–1396. 10.1128/MCB.01290-09PubMedCentralCrossRefPubMed

12.

Futami K, Kumagai E, Makino H, Sato A, Takagi M, Shimamoto A, Furuichi Y: Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci 2008,99(6):1227–1236. 10.1111/j.1349-7006.2008.00794.xCrossRefPubMed

13.

Futami K, Ogasawara S, Goto H, Yano H, Furuichi Y: RecQL1 DNA repair helicase: a potential tumor marker and therapeutic target against hepatocellular carcinoma. Int J Mol Med 2010,25(4):537–545.PubMed

14.

Arai A, Chano T, Futami K, Furuichi Y, Ikebuchi K, Inui T, Tameno H, Ochi Y, Shimada T, Hisa Y, Okabe H: RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma. Cancer Res 2011,71(13):4598–4607. 10.1158/0008-5472.CAN-11-0320CrossRefPubMed

15.

Sanada S, Futami K, Terada A, Yonemoto K, Ogasawara S, Akiba J, Yasumoto M, Sumi A, Ushijima K, Kamura T, Furuichi Y, Yano H: RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer. PLoS One 2013,8(8):e72820. 10.1371/journal.pone.0072820PubMedCentralCrossRefPubMed

16.

Yoshida H, Meng P, Matsumiya T, Tanji K, Hayakari R, Xing F, Wang L, Tsuruga K, Tanaka H, Mimura J, Kosaka K, Itoh K, Takahashi I, Imaizumi T: Carnosic acid suppresses the production of amyloid-β 1–42 and 1–43 by inducing an α-secretase TACE/ADAM17 in U373MG human astrocytoma cells. Neurosci Res 2014, 79: 83–93. 10.1016/j.neures.2013.11.004CrossRefPubMed

17.

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 2006,1(5):2315–2319. 10.1038/nprot.2006.339CrossRefPubMed

18.

Kawabe T, Tsuyama N, Kitao S, Nishikawa K, Shimamoto A, Shiratori M, Matsumoto T, Anno K, Sato T, Mitsui Y, Seki M, Enomoto T, Goto M, Ellis NA, Ide T, Furuichi Y, Sugimoto M: Differential regulation of human RecQ family helicases in cell transformation and cell cycle. Oncogene 2000,19(41):4764–4772. 10.1038/sj.onc.1203841CrossRefPubMed

19.

Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 2006, 6: 224. 10.1186/1471-2407-6-224PubMedCentralCrossRefPubMed

20.

Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J, Reed E, Neckers L: Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol 2000,60(9):1343–1354. 10.1016/S0006-2952(00)00455-XCrossRefPubMed

21.

Nyberg KA, Michelson RJ, Putnam CW, Weinert TA: Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 2002, 36: 617–656. 10.1146/annurev.genet.36.060402.113540CrossRefPubMed

22.

Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, Ikeda M, Takahashi-Yanaga F, Sasaguri T, Sekimoto M, Matsuura N, Monden M: Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 2008,99(1):129–139.PubMed

23.

de Bruin EC, Medema JP: Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008,34(8):737–749. 10.1016/j.ctrv.2008.07.001CrossRefPubMed

24.

Tao J, Tao S, Han J, Zhou Z, Zhang X, Wang H, Chen R, Ji F, Zhu Y: RECQL1 plays an important role in the development of tongue squamous cell carcinoma. Cell Physiol Biochem 2014,33(5):1579–1590. 10.1159/000358721CrossRefPubMed

Title: The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer
Authors: Yoko Matsushita
Yoshihito Yokoyama
Hidemi Yoshida
Yuki Osawa
Makito Mizunuma
Tatsuhiko Shigeto
Masayuki Futagami
Tadaastu Imaizumi
Hideki Mizunuma
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-014-0107-1

At a glance: The STEP trials

Springer Medicine

The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-Mullerian hormone

KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries

Lipid index changes in the blood serum of patients with hyperplastic and early neoplastic lesions in the ovaries

Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer

Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells

Evaluating influence of the genotypes in the follicle-stimulating hormone receptor (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: a meta-analysis